Compare PDEX & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PDEX | SCLX |
|---|---|---|
| Founded | 1978 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.5M | 90.0M |
| IPO Year | 1995 | N/A |
| Metric | PDEX | SCLX |
|---|---|---|
| Price | $39.00 | $7.93 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $56.00 | N/A |
| AVG Volume (30 Days) | 19.5K | ★ 50.9K |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 345.00 | N/A |
| EPS | ★ 2.07 | N/A |
| Revenue | ★ $66,593,000.00 | N/A |
| Revenue This Year | $7.22 | N/A |
| Revenue Next Year | N/A | $749.70 |
| P/E Ratio | $19.09 | ★ N/A |
| Revenue Growth | ★ 23.68 | N/A |
| 52 Week Low | $23.52 | $0.18 |
| 52 Week High | $70.26 | $34.27 |
| Indicator | PDEX | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 44.93 | 32.88 |
| Support Level | $37.07 | $7.78 |
| Resistance Level | $41.09 | $9.50 |
| Average True Range (ATR) | 1.57 | 0.80 |
| MACD | -0.02 | 0.15 |
| Stochastic Oscillator | 29.60 | 9.51 |
Pro-Dex Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers (OEMs) to various countries. Its product portfolio includes autoclavable, battery-powered, electric, and multi-function surgical drivers and shavers used mainly in orthopedic, thoracic, and craniomaxillofacial markets. The company also provides engineering, quality, regulatory consulting services, and manufactures rotary air motors utilized in various industries. Operating out of ISO-certified facilities in California, Pro-Dex serves hospitals, medical labs, and high-tech manufacturers, generating revenue through sales of surgical instruments and related services.
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.